ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranibizumab

Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.

Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 19, 200798 company-led studies, 6 open or runningNext primary completion: Feb 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only560 open or runningphase 4since Jul 19, 2007Jan 11, 2006none ahead
Hoffmann-La Roche244 open or runningphase 4since Jan 13, 2011Mar 24, 2003Feb 4, 2027phase 3 · NCT04657289
AbbVieits history only31 open or runningphase 4since Aug 31, 2011Oct 16, 2008Jul 2031phase 2 · NCT05210803
Samsung Bioepisits history only20 open or runningphase 2since Dec 11, 2023Dec 11, 2023none ahead
Santen Pharmaceuticalits history only20 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
AO GENERIUMits history only11 open or runningphase 3since Nov 30, 2020Nov 30, 2020none ahead
bioeq-gmbhits history only10 open or runningphase 3since Nov 19, 2015Nov 19, 2015none ahead
Cynosure Lutronicits history only10 open or runningphase 4since Nov 27, 2018Nov 27, 2018none ahead
Formyconits history only10 open or runningphase 4since Nov 25, 2024Nov 25, 2024none ahead
Incepta Pharmaceuticalsits history only10 open or runningphase 3since Mar 5, 2024Mar 5, 2024none ahead

Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Mar 24, 2003.

  1. Jun 11, 20072 phase 3 studies in Macular EdemaNCT00486018, NCT00485836
  2. Apr 29, 2009Phase 3 study in Macular DegenerationNCT00891735 · 1,097 enrolled · United States
  3. Jan 13, 2011Phase 4 study in Macular EdemaNCT01277302 · 202 enrolled · United States
  4. Sep 26, 2011No phase study in Macular EdemaNCT01442064 · 608 enrolled
  5. Jun 12, 2015Phase 2 study in Choroidal NeovascularizationNCT02484690 · 273 enrolled · United States
  6. Jul 17, 2015Phase 2 study in Macular DegenerationNCT02510794 · 225 enrolled · United States
  7. Feb 29, 2016Phase 3 study in Macular EdemaNCT02698566 · 35 enrolled · United States
  8. Aug 5, 2020Phase 3 study in Diabetic RetinopathyNCT04503551 · 174 enrolled · United States, Puerto Rico
  9. Sep 24, 2020Phase 2 study in Macular DegenerationNCT04567303 · 177 enrolled · United States, Puerto Rico
  10. Dec 1, 2020Phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)NCT04657289 · 451 enrolled · Argentina, Australia, Austria and more
  11. Apr 16, 2021Phase 4 study in Neovascular Age-related Macular DegenerationNCT04853251 · 188 enrolled · United States
  12. Oct 28, 2021Phase 3 study in Neovascular Age-Related Macular DegenerationNCT05126966 · Argentina, Denmark, Greece and more
  13. Sep 15, 2022Phase 3 study in Neovascular Age-related Macular DegenerationNCT05562947 · 68 enrolled · China
  14. Feb 21, 2025Phase 3 study in Neovascular Age-related Macular DegenerationNCT06847542 · 250 planned · Austria, Czechia, Denmark and more

Ahead

  1. Feb 4, 2027Primary completion: phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)NCT04657289
  2. Jun 30, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT05562947
  3. Jul 30, 2027Primary completion: phase 4 study in Neovascular Age-related Macular DegenerationNCT04853251
  4. Nov 15, 2028Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationNCT06847542

TargetBeta

VEGFA →read by rule
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

All 24 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06847542Neovascular Age-related Macular Degeneration · Austria, Czechia, Denmark and more3RecruitingNov 15, 2028250
NCT05562947Neovascular Age-related Macular Degeneration · China3Active, not recruitingJun 30, 202768
NCT05126966Neovascular Age-Related Macular Degeneration · Argentina, Denmark, Greece and more3WithdrawnJan 31, 20250
NCT04853251Neovascular Age-related Macular Degeneration · United States4Active, not recruitingJul 30, 2027188
NCT04657289Neovascular Age-related Macular Degeneration (nAMD) · Argentina, Australia, Austria and more3Active, not recruitingFeb 4, 2027451
NCT04567303Macular Degeneration · United States, Puerto Rico2CompletedAug 25, 2026177
NCT04503551Diabetic Retinopathy · United States, Puerto Rico3CompletedOct 3, 2022174
NCT02698566Macular Edema · United States3CompletedApr 5, 201635
NCT02510794Macular Degeneration · United States2CompletedApr 10, 2018225
NCT02484690Choroidal Neovascularization · United States2CompletedSep 26, 2017273
NCT01442064Macular Edema–CompletedJul 2010608
NCT01277302Macular Edema · United States4CompletedOct 2012202
NCT00891735Macular Degeneration · United States3CompletedAug 20111,097
NCT00486018Macular Edema3CompletedMay 2009397
NCT00485836Macular Edema3CompletedJun 2009392
NCT00473382Diabetes Mellitus3CompletedJan 2011382
NCT00473330Diabetes Mellitus3CompletedNov 2010377
NCT00379795Choroidal Neovascularization–CompletedSep 2008853
NCT00251459Choroidal Neovascularization3Completed5,000
NCT00095433Macular Degeneration3CompletedAug 2006100
NCT00090623Macular Degeneration · United States3Completed180
NCT00061594Macular Degeneration · United States, Australia, Czech Republic and more3Completed426
NCT00056836Macular Degeneration3Completed720
NCT00056823Macular Degeneration2Completed168

How it is read

Names in the registry

  • “Ranibizumab”, 40 entries
  • “ranibizumab”, 18 entries
  • “Ranibizumab 0.5 mg”, 11 entries
  • “rhuFab V2 (ranibizumab)”, 6 entries
  • “Ranibizumab 0.5mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.